JP2025511000A5 - - Google Patents

Info

Publication number
JP2025511000A5
JP2025511000A5 JP2024557573A JP2024557573A JP2025511000A5 JP 2025511000 A5 JP2025511000 A5 JP 2025511000A5 JP 2024557573 A JP2024557573 A JP 2024557573A JP 2024557573 A JP2024557573 A JP 2024557573A JP 2025511000 A5 JP2025511000 A5 JP 2025511000A5
Authority
JP
Japan
Application number
JP2024557573A
Other languages
Japanese (ja)
Other versions
JPWO2023186756A5 (https=
JP2025511000A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057751 external-priority patent/WO2023186756A1/en
Publication of JP2025511000A publication Critical patent/JP2025511000A/ja
Publication of JP2025511000A5 publication Critical patent/JP2025511000A5/ja
Publication of JPWO2023186756A5 publication Critical patent/JPWO2023186756A5/ja
Pending legal-status Critical Current

Links

JP2024557573A 2022-03-28 2023-03-27 インターフェロンガンマバリアントおよびこれを含む抗原結合分子 Pending JP2025511000A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164773.8 2022-03-28
EP22164773 2022-03-28
PCT/EP2023/057751 WO2023186756A1 (en) 2022-03-28 2023-03-27 Interferon gamma variants and antigen binding molecules comprising these

Publications (3)

Publication Number Publication Date
JP2025511000A JP2025511000A (ja) 2025-04-15
JP2025511000A5 true JP2025511000A5 (https=) 2026-04-02
JPWO2023186756A5 JPWO2023186756A5 (https=) 2026-04-02

Family

ID=80978821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557573A Pending JP2025511000A (ja) 2022-03-28 2023-03-27 インターフェロンガンマバリアントおよびこれを含む抗原結合分子

Country Status (5)

Country Link
US (1) US20250333542A1 (https=)
EP (1) EP4499229A1 (https=)
JP (1) JP2025511000A (https=)
CN (1) CN119095880A (https=)
WO (1) WO2023186756A1 (https=)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス, インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
US20180057603A1 (en) 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
MY193723A (en) 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
WO2019086499A1 (en) * 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Novel tnf family ligand trimer-containing antigen binding molecules
EP4314032A1 (en) * 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides

Similar Documents

Publication Publication Date Title
CL2025003902A1 (es) Dispositivo de aparatos de separación y máquina cosechadora de tubérculos
JP2025511000A5 (https=)
BR202022009269U2 (https=)
CN307045889S (https=)
CN307045144S (https=)
CN307048245S (https=)
CN307047953S (https=)
CN307046898S (https=)
CN307046172S (https=)
CN307046149S (https=)
CN307045860S (https=)
CN307045024S (https=)
CN307044717S (https=)
CN307044463S (https=)
CN307044420S (https=)
CN307044316S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13167U (https=)